Technologies

AN INHALED FORMULATION OF FDA-APPROVED DRUGS FOR TREATMENT OF ARDS

Type: Pharmaceuticals
Sector: Infectious Diseases-Microbiology-Virology

Prof. Rifaat Safadi and his team are developing an inhaled formulation that combines two FDA-approved drugs, which recruit and activate certain types of immune cells in patients with Acute Respiratory Distress Syndrome (ARDS).

The inhaled formulation will enable a safer use of the drugs locally in the lung.

The drugs are expected to exert a synergistic action.
Prof. Safadi's team is planning to clinically test the drugs separately and in the combined inhaled form in patients, for the benefit of COVID-19 patients.

Share this page on:

Facebook Twitter LinkedIn Email

Researcher/s:

Prof. Rifaat Safadi

Contact Info:

Tal Almog